ABSTRACT. Human recombinant erythropoietin (rHuEPO) was given i.v. to rhesus monkeys to compare its safety, erythropoietic effects, and pharmacokinetics in healthy adult and infant animals. Eighteen adult and 18 infant (9-to 15-d-old) monkeys were divided into three groups each of six animals. One group was given 250 U/ kg twice weekly, another was given 100 U/kg twice weekly, and a control group was given the drug vehicle for 6 wk.
sia (1). Affected babies may need transfusions because of clinical signs associated with impaired peripheral oxygen delivery (2) . Inadequate production of EPO, the primary regulatory hormone for erythropoiesis (3) , is thought to contribute to anemia of prematurity. Affected infants have low circulating levels of EPO (4-7) and normal numbers of peripheral blood erythroid burst forming units (8) and bone marrow colony forming units (9) . Moreover, these erythroid progenitor cells respond normally to EPO in vitro (9) . Administration of EPO has been proposed as a treatment for the anemia of prematurity (10) .
The availability of r-HuEPO has led to the development of EPO replacement therapy in adults with chronic renal failure who are anemic because of inadequate EPO production. Treatment with r-HuEPO produces dose-dependent increases in Hb concentration with few side effects (1 1, 12).
Before undertaking any clinical trials of r-HuEPO on infants with the anemia of prematurity, we believed it was important to give the drug to healthy infant experimental animals to determine whether any age-related differences existed in potential toxicity, erythropoietic effects, and pharmacokinetics. We chose infant rhesus monkeys (Macaca mulatta) because of their known hematologic similarities to human infants: a pattern of decrease of Hb concentration after birth followed by slow increase, and the rapid switch from fetal to adult Hb during the first months of life (13, 14) . We report the results of a study in which adult and newborn rhesus monkeys received r-HuEPO.
MATERIALS AND METHODS
Adult stud-v. Eighteen sexually mature rhesus monkeys were assigned to two treatment and one control group, each having three male and three female animals. They were housed individually in metal cages in compliance with the standards of the Federal Animal Welfare Act and the Institute for Laboratory Animal Resources with a 12 h light112 h dark schedule, a temperature of 20 + 6.7"C, and an average humidity of 35%.
Water was supplied ad libitum. Monkey chow (15% protein, Purina Mills, Inc., St. Louis, MO) was fed twice daily and supplemented with fresh fruit. All monkeys were healthy, as assessed by physical examination 3 d before treatment.
Monkeys received twice weekly i.v. injections of either 100 or 250 U/kg of r-HuEPO (Exprex, Amgen, Thousand Oaks, CA) or drug vehicle (human serum albumin in citrated saline) for 6 wk. All animals received intramuscular injections of 1.6 mg/kg of iron (Rogenic, Forest Pharmaceuticals, St. Louis, MO) biweekly, from 3 d before treatment until 1 d after ending treatment. Monitoring continued for 10 wk after the end of dosing.
Monkeys were weighed once before, then weekly during the the solid-phase coating. Hazleton Laboratories America, Inc. of experiment.
Vienna, VA performed this assay. Infant study. Eighteen 9-to 15-d-old rhesus monkeys weighing
The total amount of blood removed for all assays was approx-400-650 g were assigned to two treatment and one control group, imately 14 mL for infant monkeys and 34 mL for adult monkeys. each having three males and three females. They were housed This study was conducted according to good laboratory pracindividually in plastic incubators and then in metal cages, in tice regulations as defined by the Federal Register, and prescribed compliance with the standards of the Federal Animal Welfare by the Food and Drug Administration. The same manufacturer's Act and the Institute for Laboratory Animal Resources with a lots of r-HuEPO were given to infants and adults. These lots 16 h light18 h dark schedule, a temperature of 27.2 + 3.g°C, and were evaluated for activity before and after the study. No r-HuEPO-related changes occurred in total leukocyte, neud before the first dose until 3 1 d after the final dose, then weekly trophil, lymphocyte, and platelet counts, or in body weights in for the remainder of the study.
either adults (Table 1) or infants ( Table 2 ). In both treated and Study procedures. Throughout the study, all monkeys were control infant monkeys, total leukocyte and lymphocyte counts observed at least daily for signs of illness. Blood pressure was increased slowly throughout the study. Although adult but not measured (Dinamap SX, Critikon, Inc., Tampa, FL) once pre-infant monkeys had slight increases in eosinophils over time (p treatment, then weekly during the study. All blood samples were < 0.05), there were no significant differences between treatment collected by venipuncture from unsedated monkeys.
and control groups. Treated and control monkeys of both age Complete blood counts were done on EDTA anticoagulated groups did not differ in any of the serum chemistry analytes blood from adult and infant monkeys once pretreatment and measured, or in blood pressure values. As they matured, infant once during wk 3, 6, 9, 12, and 16. Red and white blood cells monkeys that had received r-HuEPO remained healthy and were were counted electronically (Coulter model ZBI, Coulter Elec-indistinguishable clinically from the control animals. tronics Inc., Hialeah, FL), Hb was measured as cyanmethemolErythrocytic Parameters of adult monkeys are summarized on globin (Coulter Hemoglobinometer, Coulter Electronics Inc.), Table 1 . Hb ~~n~e n t r a t i o n did not differ significantly among reticulocytes counted by examination of slides after staining with experimental groups of adult monkeys before treatment or after new methylene blue, and differential white blood cells counted 3 wk of r-HuEPO administration. After 6 wk of treatment, by examination of Wright stained smears. Platelets were counted monkeys given either dose of r-HuEPO had significantly higher by an automated method for adult monkeys (Baker 8 10, Baker Hb concentrations than control animals (P < 0.05). After that, I~~~~~~~~~~, ~l l~~t~~~, PA) and by hemocytometer after dilu-the Hb concentrations in treated animals fell to those of the tion with ammonium oxalate (unopette, B-D company, ~~~h -control group, with no significant differences found. Hb concenerford, NJ) for infants. Alkaline phosphatase, alanine amino tration rose slowly over the course of the study in the control transferase, total bilirubin, urea nitrogen, creatinine, and y-group, becoming significantly higher than initial values at wk 9. glutamyl transferase were measured using the same schedule as Although treated adult monkeys had slightly higher reticuloc~te hematologic studies, (Gilford Impact-400E, CIBA Corning Di-Counts than control monkeys at wk 3 and 6, these diffa-ences agnostics, Gilford Systems, Oberlin, OH).
were not statistically significant. The three adult experimental Total body Hb (TBH) was estimated for infant monkeys. groups had similar decreases in total reticulocyte count from an B~~~~~~ blood volume ofinfant monkeys has not been measured, initially high level to a low at 9 wk. Mean c o~u s c u l a r volumes total body Hb was calculated on the premise that blood volume did not differ among the adult test groups, although the overall mean of all test groups did vary over time. per kg weight did not change the and, In infant monkeys, treatment with r-HuEPO was not associtherefore, the constant X could represent it in the following formula:
ated with any significant differences between treated or control monkeys in Hb concentrations or other measured erythrocyte TBH (g) = Hb (g/dL) x body wt (kg) x (X) (dL/kg) parameters (Table 2 ). In the three test groups, the Hb concentration declined sharply by the 3rd week, then stabilized near that Pharmacokinetic studies. serum samples for pharmacokinetic level. Reticulocyte counts reached a maximum at 3 wk, then profiles were collected once before and approximately 1, 5, 10, decreased. Mean corpuscular volume decreased steadily through-15, 24, 32, and 48 h after giving the 10th dose of r-HuEPO or out the study. Calculated total body Hb increased as animals vehicle. Serum from blood samples (0.5 mL in neonates and 1.0 grew, but r-HuEPO did not produce any significant differences mL in adults) was stored at -20 to -40°C until assayed. A between treated and control groups. competitive binding RIA using antiserum to r-HuEPO obtained Pharmacokinetic profiles are summarized in Figure 1 . Baseline after immunization of New Zealand White rabbits was used to serum EPO values were below the sensitivity of the assay (5 m u / determine serum EPO concentrations. Because of the homology mL) in 15 of 18 of adult monkeys and in 16 of 18 infant monkeys, of EPO across species, endogenous rhesus monkey EPO cross-and did not increase in the monkeys given drug vehicle only. reacted with r-HuEPO in the assay. Serum taken after the 3rd Serum concentrations of r-HuEPO at 1 h were significantly lower and 12th doses of r-HuEPO was tested for the presence of in infants than in adults given the same dosage (p < 0.05). Serum antibodies against r-HuEPO by an ELISA that used r-HuEPO as r-HuEPO levels in adult monkeys 1 h after receiving 100 U/kg t Control values significantly higher than baseline, but no significant difference among groups ( p < 0.05).
$ Significant differences in overall mean over time, but no significant differences among groups ( p < 0.05).
approximated those found in infant monkeys that received 250 U/kg. The apparent volume of distribution, estimated by dividing the dose by the zero-h serum r-HuEPO concentration, as extrapolated from the curve in Figure 1 , was 35.7 mL/kg in adults and 77 mL/kg in infants. A 2.5-fold increase in i.v. dose resulted in a proportionate increase in peak serum concentrations in both infant and adult monkeys. The overall mean tjI2 of all experimental groups for r-HuEPO in serum was 2.5 f 0.4 h, with no significant difference found among the groups. None of the monkeys developed antibodies to r-HuEPO.
to that compound. Both adult treatment groups had significant increases in Hb concentration, as have other adult experimental animals given r-HuEPO, including mice (16), dogs, rats, and cynomolgus monkeys (R. W. Johnson Pharmaceutical Research Institute, unpublished data). The significantly lower serum concentrations of r-HuEPO in infant monkeys given the same dose as adults may have contributed to this age-related difference. The volume of distribution that we calculated for adult monkeys (35.7 mL/kg) is close to their reported plasma volume (17) . Similarly, the volume of distribution for EPO in adult sheep and rats equals their plasma volumes (18, 19) . If r-HuEPO also distributes to the plasma volume in infant animals, one would expect lower serum concentrations per unit of dose because infants have larger plasma volume per kg than adults of the same species. We did not find any published values for plasma volume of infant rhesus monkeys. The volume of distribution calculated for r-HuEPO in infant rhesus monkeys (77 mL/kg) is larger than plasma volume reported for infants of other animal species (17) and human infants (20) .
Other explanations for this large calculated volume of distribution would be that r-HuEPO distributes in infant monkeys to a larger space than plasma volume, or that the first rate of removal was missed in this study by the necessity of a limited sampling schedule in these small animals. Plasma volume measurements on infant rhesus monkeys and more detailed pharmacokinetic measurements during the first hours after administration would be helpful in determining which of these explanations is correct.
Differences in serum concentration, however, cannot completely explain the age-related difference we found. Infant mon- DISCUSSION We administered r-HuEPO to rhesus monkeys to compare its safety, erythropoietic effects, and pharmacokinetics in healthy infant and adult animals. No adverse effects were associated with r-HuEPO treatment in either infant or adult monkeys. Neither thrombocytosis, thrombosis, nor hypertension, reported complications of r-HuEPO therapy in human renal failure patients (1 1, 12, 15), developed in either adult or infant monkeys. No rHuEPO-associated leukocyte changes occurred in either age group. The only unexpected change in adult monkeys was a slight increase in eosinophil count during the experiment. A possible explanation is a low-grade allergic reaction to either the human serum albumin in the drug vehicle or the peptonized iron, two compounds administered to all adult animals.
We did not find significant differences in Hb concentrations between treated and control infant monkeys after either 3 or 6 wk of r-HuEPO administration. Lack of erythropoietic response to administered r-HuEPO in infant monkeys was not the result of an intrinsic inability of rhesus erythroid progenitors to respond * Significant differences in overall mean over time, but no significant differences among groups ( p < 0.05).
keys that received 250 U/kg of r-HuEPO achieved similar peak serum levels as adult monkeys that received 100 U/kg, yet they did not increase erythrocyte production above control values, as the adults did. Less iron might have been available to the infant monkeys for increased erythropoiesis. Iron deficiency is a major cause of r-HuEPO therapy failure in patients with chronic renal disease (1 1, 12, 15). Infant animals of any species are in precarious iron balance resulting from multiple demands of growth, expanding blood volume, and limited amounts of storage and dietary iron (21) . Erythropoiesis was active in the infant monkeys, as shown by reticulocytosis and increasing total body Hb. Those given r-HuEPO might have lacked enough iron to increase erythropoiesis above that being stimulated by their endogenous EPO. We based iron supplementation on the recommended level for human term infants of 2 mg/kg total dietary iron (22) . Infant rhesus monkeys may need higher levels of iron because of their shorter gestation period, smaller size, and more rapid growth rate. We did not perform any laboratory tests to measure iron balance because we wanted to keep the volume of blood removed from these small animals to a minimum. Low-grade iron deficiency might have also existed in the adult monkeys. Hb concentration increased slowly in control monkeys, which received supplemental iron. Recently, subclinical iron deficiency has been recognized as a problem in adult monkeys at the California Primate Research Center (23) . The use of parenteral iron, which is available for erythropoiesis sooner than oral iron, may have allowed the adult monkeys to increase Hb during r-HuEPO administration. Although iron deficiency did not prevent response to r-HuEPO, it may have blunted it; both treatment groups had similar Hb concentrations during r-HuEPO administration.
It is possible that the active erythroid bone marrow of infant monkeys responds differently to r-HuEPO than the marrow of adult rhesus monkeys. The target cells of r-HuEPO might have been exposed to fewer than the needed number of EPO molecules for stimulation, resulting from the combination of larger dilutional space and greater numbers of erythroid progenitor cells in infant monkeys. Although it is possible that erythroid progenitors of infant monkeys are intrinsically less responsive to r-HuEPO than adult cells, there are no data to support this hypothesis. Erythroid progenitors cultured from human fetuses and premature and term babies respond at least as well to r-HuEPO as adult progenitors (8, 9, 24) . Although no in vitro work using rhesus monkey bone marrow has been published, fetal baboon bone marrow cultures stimulated by r-HuEPO had a pattern of erythroid burst growth similar to that seen in adults (25) . Studies giving higher doses of r-HuEPO to infant monkeys supplemented with more iron, as well as in vitro experiments to compare the patterns of erythroid progenitor growth from adult and infant rhesus monkeys over a range of r-HuEPO concentrations, would help determine whether iron or age-related erythroid progenitor insensitivity are important limiting factors in their response to rHuEPO.
Although the pattern of erythropoiesis in healthy infant rhesus monkeys differs from that in anemic premature babies, the results of our study provide new information that augments limited data from recent studies on use of r-HuEPO in anemia of prematurity (26, 27) . The lack of any adverse effects of r-HuEPO in infant monkeys supports the concept that further placebocontrolled clinical trials of r-HuEPO therapy in anemia of prematurity are warranted. Particularly important was the finding that infant monkeys given r-HuEPO at doses higher than those given to human infants did not develop neutropenia or thrombocytosis. Both were reported in seven premature infants given Fig. 1 . M e a n serum r-HuEPO concentration. T h e 100 U/kg dose i n adults produces approximately t h e s a m e concentration a t 1 h as t h e 250 U/kg dose in infants. T h e slopes of all elimination curves are similar.
r-HuEPO in an uncontrolled study (27) , although they did not occur in a larger, placebo-controlled study (26) . Secondly, the erythropoietic response to r-HuEPO of infants cannot be predicted from the responses of adults of the same species. Our data in infant rhesus monkeys are consistent with the observation that human premature infants given r-HuEPO in doses known to be effective in adults had either no increase (26) or a very slight increase (27) in Hb production. Preterm human babies have large plasma volumes compared with adults; dosage schedules designed for adults may produce lower circulating r-HuEPO concentrations, as we found in infant monkeys. Furthermore, iron deficiency occurred in some babies treated unsuccessfully with r-HuEPO (27) . Higher amounts of iron, perhaps even parenteral iron, may need to be given during r-HuEPO therapy for optimal erythropoiesis in both infant rhesus monkeys and premature babies. When viewed together, our work and the two pilot studies of r-HuEPO therapy in anemia of prematurity are complementary, but leave some important practical and theoretical questions about its use in infancy unanswered. Erythropoiesis in infant rhesus monkeys may prove to be a useful animal model for further investigation of the use of r-HuEPO in premature babies.
